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The data from
RCTs represents
the beginning of
the decision-making
process, not the end.
The experience
and wisdom of a
thoughtful physi-
cian can make an
important contri-
bution to the appli-
cation of the evi-
dence base that is
available.ardiovascular specialists have become justifiably proud of their commitment to
evidence-based medicine and clinical trials. More large-scale randomized pro-
spective clinical trials (RCTs) are performed in cardiology than in any other field,
nd contemporary practice is nearly always based upon at least one such study. By controlling
ariables, minimizing subconscious bias, and insuring data of adequate power and statistical
alidity, megatrials provide results that are seen as definitive in areas of equipoise. They con-
ey guidance to physicians whose individual practices could not reveal the subtle benefits
or detriments) of specific management alternatives that can be delineated by large study
opulations. We have come to rely on trial data so much that trainees sometimes now
eel paralyzed to make a decision in the absence of data from an RCT.
The proliferation of clinical trials has raised questions regarding the role of clinical
udgment in contemporary medicine and how best to incorporate the results of trials
nto clinical practice. In fact, compared with the wealth of data from RCTs, there has
een a paucity of studies regarding how to convert these findings into “real-world” set-
ings (1). For all of their attributes, clinical trials have a number of limitations. In my
iew, the time has come to acknowledge these limitations and re-emphasize the impor-
ant role of clinical judgment in interpreting research findings and applying them to in-
ividual patients.
As previously stated, clinical trials have a number of limitations. The end points listed
re not always optimal. Patients are interested in survival, lack of morbidity, and quality
f life; society also values cost effectiveness. However, trials often use surrogate end
oints. In addition to often being of little importance to patients, surrogates may lead to
isleading and erroneous conclusions. The classic example is CAST (Cardiac Arrhyth-
ia Suppression Trial), where suppression of premature ventricular contractions resulted
n more mortality rather than less (2). More recently, torcetrapib decreased survival de-
pite increasing high-density lipoprotein (3). Trials often employ composite end points
hat, although they enable assessment of nonfatal events, entail a number of shortcom-
ngs. The individual events are not always of similar magnitude (e.g., death vs. rehospi-
alization) and some events, such as the need for a subsequent procedure, are significant
rimarily in regard to timing. Clinical trials often employ extensive subgroup analysis.
owever, multiple testing can lead to chance findings; the ISIS (International Study of
nfarct Survival) trial demonstrated variability in the efficacy of aspirin in groups identi-
ed by their astrological sign (4). To be of value, analysis of subgroups should be pre-
pecified and involve adequate sample size.
A number of difficulties arise when applying the findings of clinical trials to everyday
ractice. Therapies may have multiple effects that may not be tested. The cyclooxygen-
se-2 inhibitor VIOXX (Merck, Whitehouse Station, New Jersey) had adverse cardio-
ascular effects that may have been somewhat obscured by the focus upon gastrointesti-
al end points and would be of particular importance in patients with coronary artery
isease. Drug–drug interactions are common and may be encountered more frequently
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March 18, 2008:1120–2 Editor’s Pagen the “real world” than in trials. Not all agents in a given
lass may share the same efficacy, a characteristic exhib-
ted by beta-blockers. In addition, the benefit of therapy
ay be time limited, and this interval may not be exam-
ned by the trial. The risk of late stent thrombosis of
rug-eluting stents presents such an example.
The biggest limitation of clinical trials is that they deal
ith rigidly-defined patient populations in a highly-con-
rolled fashion. My colleague (and JACC Associate Edi-
or) Barry Greenberg has likened trials to “Muzak” (bland
ackground music sometimes referred to as “elevator” or
telephone on hold” music) as compared with clinical
ractice, which is analogous to Mozart. Clinical practice
eals with broad patient populations from all strata of
ociety, with diverse etiologies, variable durations and de-
rees of disease, and frequent comorbidities. Like Mozart,
t is heterogeneous and expansive. In contrast, RCTs usu-
lly deal with narrow populations with restricted etiologies
nd severity of disease in whom most comorbidities have
een excluded. Like Muzak, they tend to be homogenous
nd confined. It is not surprising, therefore, that the re-
ults of clinical trials are frequently not easily translated to
ndividual patients.
The confined nature of clinical trials can result in some
mportant limitations. For example, the SOLVD (Studies
f Left Ventricular Dysfunction) trial (5), which demon-
trated the benefit of angiotensin-converting enzyme inhi-
ition with enalapril, excluded patients with an ejection
raction 35%, age 79 years, and creatinine 2 mg/dl.
eart failure patients encountered in clinical practice of-
en manifest these characteristics. The SOLVD trial en-
olled 80% males. In the recent landmark COURAGE
Clinical Outcomes Utilizing Revascularization and Ag-
ressive Drug Evaluation) trial, 36,000 patients were
creened, of which 3,071 were eligible to participate and
,287 (6.3%) were ultimately enrolled (6). The implica-
ions of such potential enrollment bias are obvious.
Another factor complicating the application of clinical
rial results to practice is the issue of lack of publication
f negative trials. Studies in which the intervention exam-
ned is not of benefit are less attractive to publish for both
uthors and editors, and in fact often are never published.
hus, these negative results may not be available to offset
ositive findings, resulting in a skewed impression on the
art of the physicians. While mandated registration of
rials may alleviate some of the problems of negative stud-
es, it remains uncertain whether such results will have
omparable impact to well-publicized positive data.
In addition to the aforementioned issues involved in
ranslating trial findings to practice, problems may be en-
ountered when physicians apply results in a fashion not aollowed in the study. After publication of the RALES
Randomized Aldactone Evaluation Study) trial, an in-
rease in the use of spironolactone was observed in heart
ailure patients who were treated outside of the bound-
ries specified in the protocol (7). Such management re-
ulted in an increase in complications compared with
hose encountered by patients in the RALES trial.
Given the issues delineated above, it appears that an
mportant role for clinical judgment should exist in apply-
ng the data from clinical trials. In fact, evidence exists to
alidate this concept. In a clever experiment recently pub-
ished in JACC, Pereira et al. (8) from MASS (Medicine,
ngioplasty, or Surgery Study) II had 2 cardiologists in-
icate their treatment preference prior to randomizing
atients to percutaneous or surgical revascularization. Pa-
ients who were randomized to treatment concordant with
he preference of the cardiologists had a lesser event rate
han those in whom the form of revascularization was
iscordant with the wishes of the cardiologists. These
ata are consistent with findings from the EAST (Emory
ngioplasty versus Surgery Trial) (9) and BARI (Bypass
ngioplasty Revascularization Investigation) (10) trials, in
hich patients qualifying for enrollment but who partici-
ated only in the registry did slightly better than those pa-
ients who were randomized. In aggregate, these data sup-
ort the value of clinical judgment in synthesizing trial data
nd patient factors to select optimal patient management.
At this point, it should be emphasized that I am a pro-
onent of clinical trials and the evidence-based medicine
hat can result. It is clear that retrospective observational
tudies are subject to the influence of uncontrolled vari-
bles, and that no single physician can catalogue sufficient
bservations from his or her own practice to detect mod-
st changes in benefit or risk. Numerous studies, such as
he ACC GAP (American College of Cardiology Guide-
ines Applied in Practice) project, have demonstrated that
uidelines-based standardized care is associated with a
eduction in mortality from acute myocardial infarction
11). Neither would I contest that therapies of proven
fficacy are often underutilized. I believe that clinical trials
rovide very valuable data to guide patient care decisions.
just believe that the data from RCTs represents the be-
inning of the decision-making process, not the end.
As I said at the beginning of this piece, cardiovascular
pecialists should be justifiably proud of their leadership
n performing clinical trials. However, the importance and
nfallibility of clinical trials has likely been overempha-
ized at the expense of clinical judgment. The megatrials
re far from perfect, and at best provide guidance for the
are of individual patients. The experience and wisdom of
thoughtful physician can make an important contribu-
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Editor’s Page March 18, 2008:1120–2ion to the application of the evidence base that is avail-
ble. Although this may not be welcomed by some out-
ide of medicine, it should be of great comfort to those of
s inside the profession.
ddress correspondence to:
r. Anthony N. DeMaria
ditor-in-Chief, Journal of the American College of Cardiology
655 Nobel Drive, Suite 630, San Diego, California 92112
-mail: ademaria@acc.org
EFERENCES
1. DeMets DL, Califf RM. Lessons learned from recent clinical trials.
Circulation 2002;106:746–51.
2. Cardiac Arrhythmia Suppression Trial (CAST) Investigators. Effect
of encainide and flecainide on mortality in a randomized trial of
arrhythmia suppression after myocardial infarction. N Engl J Med
1989;321:405–12.
3. Barter PJ, Caulfield M, Eriksson M, et al. Effects of torceptrapib in
patients at high risk for coronary events. N Engl J Med 2007;357:
2180–3.4. ISIS 2 Collaborative Group. Randomized trial of intravenous strep-
tokinase, oral aspirin, both or neither among 17,187 cases of suspected
acute myocardial infarction. Lancet 1988;2:349–60.
5. The SOLVD Investigators. Effect of enalapril on mortality and the
development of heart failure in asymptomatic patients with reduced
left ventricular ejection fractions. N Engl J Med 1992;327:685–91.
6. Boden WE, O’Rourke FA, Teo KK, et al. Optimal medical therapy
with or without PCI for stable coronary disease. N Engl J Med
2007;356:1503–16.
7. Bozkurt B, Agoston I, Knowlton AA. Complications of inappropriate
use of spironolactone in heart failure: when an old medicine spirals out
of new guidelines. J Am Coll Cardiol 2003;41:211–4.
8. Pereira AC, Lopes NHM, Soares PR, et al. Clinical judgment and
treatment options in stable multivessel coronary artery disease: results
from the one-year follow-up of the MASS II (Medicine, Angioplasty,
or Surgery Study II). J Am Coll Cardiol 2006;48:948–53.
9. King SB III, Lembo NJ, Weintrub WS, et al. The Emory
angioplasty versus surgery trial. A randomized trial comparing
coronary angioplasty with coronary bypass surgery. N Engl J Med
1994;331:1044–50.
0. The Bypass Angioplasty Revascularization Investigation Investigators.
Comparison of coronary bypass and angioplasty in patients with
multivessel disease. N Engl J Med 1996;335:217–25.
1. Eagle KA, Montoye CK, Riba AL, et al. Guideline-based standard-
ized care is associated with substantially lower mortality in Medicare
patients with acute myocardial infarction. J Am Coll Cardiol 2005;
46:1242–8.
